About Grand Mount Capital
Grand Mount Capital is a venture capital firm founded in 2019. It is primarily based out of Jing'an, China. As of Sep 2021, Grand Mount Capital has invested in 20 companies. It primarily invests in Series B round in China based startups. Its investments are spread across a wide range of sectors from Life Sciences to High Tech and HealthTech. Most recently it participated in the $***** Series B round of Jinshi Technology Overall, Grand Mount Capital portfolio has seen 5 IPOs and 1 acquisition including key companies like Shanghai Henlius Biotech, Mindray and Gland Pharma. A lot of funds co-invest with Grand Mount Capital, with names like Maison Capital sharing a substantial percentage of its portfolio.Key Metrics
Portfolio Count
Portfolio Sectors
Portfolio Locations
Rounds of Entry
Series B, Series A & 1 more
Portfolio IPOs
Portfolio Acquisitions
Grand Mount Capital's List of Top Investments
Grand Mount Capital has a portfolio of 20 companies. Their most notable investments include Shanghai Henlius Biotech and Mindray.Their portfolio spans across China, United States, France and 1 more locations. They have invested in Life Sciences, High Tech, HealthTech and 1 other sectors, across stages such as Series B, Series A and 1 more. Here is the list of top investments by Grand Mount Capital:Shanghai Henlius Biotech is the biotech arm of Fosun Pharmaceuticals. It was formed as a joint venture company by Shanghai Fosun Pharmaceuticals and Henlius Biopharmaceuticals. The company develops, produces, and commercializes monoclonal antibody (mAb) drugs. The company focuses on developing mAb-based therapeutics, including mAb biosimilar, biobetters, mAb, bispecific antibody drugs, and antibody drug conjugates, etc. Products currently in development cover a variety of therapeutic areas including oncology and autoimmune diseases. As of July 2017, they have completed the IND submissions of 8 products for 13 indications. The first 5 of them HLX01 to HLX05 are biosimilars of global blockbuster drugs. HLX07 is their biobetter candidate targeting colorectal cancer, head, and neck cancer and is currently undergoing clinical trials in China and Taiwan.
Key facts about Shanghai Henlius Biotech
- Founded Year: 2010
- Location: Xuhui (China)
- Stage: Public
- Total Funding till date: $347M
- Employee Count: 496 as on Mar 31, 2026
- Investors: GT Healthcare Capital Partners, ShenZhen GTJA Investment Group and 10 Others
- Latest Funding Round: Series B, Jul 19, 2018, $*****
- Highlight: Public
2. Mindray
Provider of medical equipment & accessories for both human and veterinary. It provides solutions for patient monitoring, anesthesia, and ultrasound. It also provides care for variety of animals. In 2022, the company recorded annual revenues of $4.58B and a net profit of $1.47B.
Key facts about Mindray
- Founded Year: 1991
- Location: Shenzhen (China)
- Annual Revenue: ₹1,220Cr as on Mar 31, 2025
- Stage: Public
- Employee Count: 67 as on Nov 14, 2025
- Investors: Goldman Sachs, RiverHead Capital and 17 Others
- Latest Funding Round: Series A, 2003, $*****
- Highlight: Public
3. Gland Pharma
Manufacturer of generic injectable drug. It focus on meeting diverse injectables needs with a stable supply of products. It have established a portfolio of injectables products across various therapeutic segments and delivery systems and are present in sterile injectables, oncology and ophthalmics with a focus on complex injectables.
Key facts about Gland Pharma
- Founded Year: 1978
- Location: Hyderabad (India)
- Annual Revenue: ₹5,830Cr as on Mar 31, 2025
- Stage: Public
- Total Funding till date: $209M
- Employee Count: 3,846 as on Feb 28, 2026
- Investors: ICICI Venture, InvAscent and 58 Others
- Latest Funding Round: Unattributed, Nov 28, 2013, $*****
- Highlight: Public
4. HiFiBiO
Provider of a technology platform for the discovery of antibody-based drugs. The platform combines high throughput, single-cell, functional-based screening of entire B cell (Ab producing cells) populations with next-generation sequencing and rapid DNA synthesis for rare antibody drugs.
Key facts about HiFiBiO
- Founded Year: 2013
- Location: Paris (France)
- Stage: Series D
- Total Funding till date: $180M
- Employee Count: 39 as on Mar 31, 2026
- Investors: Sequoia Capital, LYFE Capital and 20 Others
- Latest Funding Round: Series D, Jun 14, 2021, $*****
- Highlight: Editors' Pick
Biotech company that develops and commercializes next-generation sequencing based integrated solutions for clinical applications. Focuses majorly on genetic testing and oncology testing. It is one of the leading providers of non-invasive prenatal testing (NIPT) in China. Its products include NextSeq CN500 gene sequencing platform and supply of consumables to the sequencing system. In Dec 2016, the company went public on China's Shenzhen market via a reverse merger with Chengdu Tianxing Instrument & Meter, a shell auto company, in a deal that values Berry Genomics at $618.8M.
Key facts about Berry Genomics
- Founded Year: 2010
- Location: Beijing (China)
- Stage: Public
- Total Funding till date: $16M
- Investors: TMCP, Qiming Venture Partners and 6 Others
- Latest Funding Round: Series B, Apr 02, 2015, $*****
- Highlight: Public
Grand Mount Capital's Year-on-Year Investment Trends
Grand Mount Capital has invested in 20 companies over the last 5 years, with an average of 1 new investment annually in the last 5 years. Its most recent first time investment was in Jinshi Technology.Grand Mount Capital's Investments by Stage
Grand Mount Capital has made 4 investments in Series B stage with an average round size of $33.6M, 1 investment in Series A stage with an average round size of $15.5M and 1 investment in Series D stage with an average round size of $75M.Stage of entry | No. of Investments |
|---|---|
Series B | 4 |
Series A | 1 |
Series D | 1 |
Note: We have considered here, only first round of investments
Grand Mount Capital's Investments by Sector
Grand Mount Capital has a diverse portfolio, with companies operating in the Life Sciences, Healthcare and High Tech. Notably, it has invested in 14 Enterprise (B2B) companies, 11 Tech companies, 2 Consumer (B2C) companies and at least 2 companies focusing on Software.Sector | No. of Investments |
|---|---|
Life Sciences | 4 |
Healthcare | 2 |
High Tech | 2 |
Note: We have considered here, only first round of investments
Grand Mount Capital's Investments by Geography
Grand Mount Capital has made most investments in China (5), followed by France where it has made 1 investment.Country | No. of Investments |
|---|---|
China | 5 |
France | 1 |
Note: We have considered here, only first round of investments
Grand Mount Capital's recent investments
Grand Mount Capital has not made any investment in 2026 so far.Here are the most recent investments by Grand Mount Capital:
Filter this listDate | Company | Location | Round Details | Round Amount | Co-Investors |
|---|---|---|---|---|---|
Sep 29, 2021 | China | Series B | 4880 | [+5] | |
Sep 18, 2021 | China | Series B | 3532 | ||
Sep 2021 | China | Series A | 8915 | [+2] | |
Jun 29, 2021 | China | Series B | 3747 | ||
Jun 14, 2021 | France | Series D | 3778 | [+9] |
IPOs and Publicly Listed companies in Grand Mount Capital's Portfolio
5 of Grand Mount Capital's portfolio companies have become public. Gland Pharma got listed on the Bombay Stock Exchange (BSE), National Stock Exchange (NSE), in Nov 2020 at marketcap of $3.3B and Shanghai Henlius Biotech got listed on the Hong Kong Exchanges (HKG) at marketcap of $3.41B.Here are Grand Mount Capital's portfolio companies that went public:
Company | IPO Date | First Invested on | First Round of Investment | Round Size |
|---|---|---|---|---|
Nov 20, 2020 | - | - | 2662 | |
Sep 25, 2019 | - | - | 3104 | |
Oct 16, 2018 | - | - | 5459 | |
Oct 16, 2018 | - | - | 7419 | |
Dec 25, 2016 | - | - | 3685 |
Acquired companies in Grand Mount Capital's Portfolio
1 company from Grand Mount Capital's portfolio has been acquired. The most recent acquisition were United Family Healthcare in Jul 2019 by New Frontier for $1.44B.Here are Grand Mount Capital's portfolio companies that got acquired most recently:
Company | Acquisition Date | First Invested on | First Round of Investment | Round Size |
|---|---|---|---|---|
Jul 30, 2019 | - | - | 4189 |
Co-investors of Grand Mount Capital
Over the past 5 years, 53 investors have co-invested in Grand Mount Capital's portfolio companies. This includes funds and angels.
- Invested before Grand Mount Capital: Sequoia Capital, IDG Capital and 18 others have invested in rounds before Grand Mount Capital. There is 1 company where Sequoia Capital has invested before Grand Mount Capital and 1 company where IDG Capital has invested before Grand Mount Capital.
- Top Co-investors of Grand Mount Capital: 22 investors entered a company along with Grand Mount Capital. These include investors like Maison Capital (2 companies).
- Invested after Grand Mount Capital: A total of 11 investors have invested in Grand Mount Capital's portfolio after their investments. Top Investors include CMB International Capital (1 company), Sunshine Insurance Group (1 company) and CMG-SDIC Capital (1 company).
Recent News related to Grand Mount Capital
•
Precision Scientific produces series B roundGlobal Corporate Venturing•Sep 21, 2021•Precision Scientific, Guotai Junan Securities, Polaris Capital, Grand Mount Capital and 2 others
•
•
•
Gaocheng Biotechnology completes Series D financing, led by Mirae Asset Financial GroupPEdaily•Jun 14, 2021•HiFiBiO, Mirae Asset, BCG, Sherpa Healthcare Partners and 7 others
